ID   MOLT-17
AC   CVCL_2125
SY   Molt-17; MOLT 17; MOLT17
DR   BTO; BTO:0004174
DR   CLO; CLO_0051012
DR   CLDB; cl3517
DR   BioSample; SAMN03472051
DR   Cell_Model_Passport; SIDM00430
DR   Cosmic; 933539
DR   Cosmic; 1118461
DR   Cosmic; 2602928
DR   DSMZ; ACC-36
DR   DSMZCellDive; ACC-36
DR   GEO; GSM5137762
DR   NCBI_Iran; C516
DR   PRIDE; PXD023662
DR   RCB; RCB1982
DR   RCB; RCB4561
DR   TKG; TKG 0385
DR   Wikidata; Q54906348
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=2784121;
RX   PubMed=2961573;
RX   PubMed=8127147;
RX   PubMed=8641406;
RX   PubMed=35354797;
WW   https://cell.brc.riken.jp/en/announcement/molt-17
CC   Problematic cell line: Partially contaminated. The RCB/Riken RCB1982 stock was contaminated and was replaced by RCB4561 which originates from DSMZ ACC-36. On the basis of STR profile, the version at TKG (TKG 0385) seems to be identical or closely related to the RCB1962 contaminated stock.
CC   Population: African American.
CC   Doubling time: ~50 hours (DSMZ=ACC-36).
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Discontinued: RCB; RCB1982; true.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: T-cell; CL=CL_0000084.
ST   Source(s): DSMZ; RCB; TKG
ST   Amelogenin: X
ST   CSF1PO: 9,10,12 (RCB_RCB1982)
ST   CSF1PO: 10,12 (TKG)
ST   CSF1PO: 11,12 (DSMZ)
ST   D13S317: 10,11,12 (RCB_RCB1982)
ST   D13S317: 10,12 (TKG)
ST   D13S317: 12 (DSMZ)
ST   D16S539: 9,10 (DSMZ)
ST   D16S539: 9,14,15 (RCB_RCB1982)
ST   D16S539: 9,15 (TKG)
ST   D18S51: 14,15,20
ST   D19S433: 10,13
ST   D21S11: 32.2,33.2
ST   D2S1338: 19,21
ST   D3S1358: 14,17
ST   D5S818: 11,12 (DSMZ)
ST   D5S818: 12 (TKG)
ST   D5S818: 12,13 (RCB_RCB1982)
ST   D7S820: 11 (TKG)
ST   D7S820: 11,12,13 (RCB_RCB1982)
ST   D7S820: 12 (DSMZ)
ST   D8S1179: 14
ST   FGA: 23,24
ST   Penta D: 6,10
ST   Penta E: 16
ST   TH01: 9 (RCB_RCB1982; TKG)
ST   TH01: 9,9.3 (DSMZ)
ST   TPOX: 8 (RCB_RCB1982; TKG)
ST   TPOX: 8,11 (DSMZ)
ST   vWA: 16 (DSMZ)
ST   vWA: 17,18,19 (RCB_RCB1982)
ST   vWA: 18,19 (TKG)
DI   NCIt; C7953; Childhood T acute lymphoblastic leukemia
DI   ORDO; Orphanet_99861; Precursor T-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_1424 ! MOLT-16
SX   Female
AG   5Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 24
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=2784121; DOI=10.1002/hon.2900070203;
RA   Drexler H.G., Minowada J.;
RT   "Morphological, immunophenotypical and isoenzymatic profiles of human
RT   leukemia cells and derived T-cell lines.";
RL   Hematol. Oncol. 7:115-125(1989).
//
RX   PubMed=2961573; DOI=10.1002/eji.1830171208;
RA   Tighe L., Forster A., Clark D.M., Boylston A.W., Lavenir I.,
RA   Rabbitts T.H.;
RT   "Unusual forms of T cell gamma mRNA in a human T cell leukemia cell
RT   line: implications for gamma gene expression.";
RL   Eur. J. Immunol. 17:1729-1736(1987).
//
RX   PubMed=8127147;
RA   Heyman M., Grander D., Brondum-Nielsen K., Cederblad B., Liu Y.,
RA   Xu B., Einhorn S.;
RT   "Interferon system defects in malignant T-cells.";
RL   Leukemia 8:425-434(1994).
//
RX   PubMed=8641406; DOI=10.1111/j.1600-0609.1996.tb00721.x;
RA   Borgonovo-Brandter L., Heyman M., Rasool O., Liu Y., Grander D.,
RA   Einhorn S.;
RT   "p16INK4/p15INK4B gene inactivation is a frequent event in malignant
RT   T-cell lines.";
RL   Eur. J. Haematol. 56:313-318(1996).
//
RX   PubMed=35354797; DOI=10.1038/s41467-022-29224-5;
RA   Leo I.R., Aswad L., Stahl M., Kunold E., Post F., Erkers T.,
RA   Struyf N., Mermelekas G., Joshi R.N., Gracia-Villacampa E.,
RA   Ostling P., Kallioniemi O.-P., Pokrovskaja Tamm K., Siavelis I.,
RA   Lehtio J., Vesterlund M., Jafari R.;
RT   "Integrative multi-omics and drug response profiling of childhood
RT   acute lymphoblastic leukemia cell lines.";
RL   Nat. Commun. 13:1691.1-1691.19(2022).
//